Antibacterial agent 128
Antibacterial agent 128 is a siderophore analog-Ciprofloxacin (HY-B0356) conjugate with a cleavable linker. Antibacterial agent 128 shows antibiotic activities against P. aeruginosa (MIC values of 0.25-64 μg/mL) and B. pseudomallei (MIC values of 1-32 μg/mL).
For research use only. We do not sell to patients.
- CAS No.: 3059046-75-9
- Formula: C26H25FN4O9
- Molecular Weight:556.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Antibiotic Isoforms
More
Biological Activity
Description
IC50 & Target
MIC: 0.25-64 μg/mL (P. aeruginosa), 1-32 μg/mL (B. pseudomallei), 4-128 μg/mL (B. thailandensis)[1]
In Vitro
Antibacterial agent 128 (compound 2d), bearing an hydroxypyridinone moiety with a cleavable linker, active on a large panel of strains of P. aeruginosa (MIC = 0.25-64 μg/mL), B. pseudomallei (MIC = 1-32 μg/mL) and B. thailandensis (MIC = 4-128 μg/mL). Moreover, Antibacterial agent 128 is active on the P. aeruginosa Ciprofloxacin-resistant strain AM85 without cytotoxicity[1].
Using iron transport systems is a promising strategy to bypass the bacteria cell membrane and restore the activity of conventional antibiotics such as Ciprofloxacin. The siderophore analogs correspond to a mono-catechol or a hydroxypyridinone moiety recognized by both Pseudomonas and Burkholderia species. Physico-chemical studies show that (i) conjugates were unable to interact or cross the membrane by passive diffusion and (ii) conjugates with cleavable linker are stable in physiologic environment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 3059046-75-9
-
Molecular Weight 556.50
-
Formula C26H25FN4O9
-
SMILES
CC(OC(N1CCN(CC1)C2=CC3=C(C(C(C(O)=O)=CN3C4CC4)=O)C=C2F)=O)OC(C5=CC(C(O)=CN5)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)